ClinicalTrials.gg
CompletedNCT06664502Updated Aug 24, 2026

A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

A Phase 1/2 interventional study of EYE201 in Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD) and BRVO - Branch Retinal Vein Occlusion, sponsored by EyeBiotech Ltd.. Completed at 27 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by EyeBiotech Ltd. (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 106 studies in Retinal Vein Occlusion with a site in United States — 6 open to participants now, 10 under way, 1 of them phase 3. Retinal Vein Occlusion · United States.

Enrollment
48th of 90
38 · median 40
Started
2024
the only one that year
Phase 1/2
9 of 106
none open now
Registered
101st of 106
by date

Among the 106 studies in Retinal Vein Occlusion with a site in United States, this one is the 48th largest by enrollment of the 90 interventional ones that give a count, is the only one that started in 2024, is one of 9 in phase 1/2, and was the 101st registered.

Retinal Vein Occlusion

289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.

Browse Retinal Vein Occlusion studies →

Open to participants now

6 of the 106 studies in Retinal Vein Occlusion with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Retinal Vein Occlusion with a site in United States, or all of them as a file.
02

Study summary

EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201.

All participants in the study will receive a total of 3 injections of EYE201 into the study eye, spaced at 4 weeks apart.

In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE201 will be assessed at increasing doses in branch retinal vein occlusion (BRVO) participants. Approximately 12 participants will be entered in this part of the study.

In the second part of the study, called the dose finding part, 2 doses of EYE201 will be selected and their effectiveness will be compared. This portion of the study assesses the safety and preliminary efficacy of EYE201 in patients with diabetic macular edema (DME) or neovascular macular degeneration (NVAMD). Approximately 80 participants will be entered in this part of the study.

Read the detailed description

In the multiple ascending dose (MAD) part of the study, 4 cohorts, each comprised of 3 participants, will receive IVT injections of EYE201 at one of 4 dosing levels in ascending order in an open label design. The participants will have previously untreated (naïve) BRVO and will receive EYE201.

Participants will return for safety and efficacy assessments and sample collection study visits. Participants in the following cohort will receive their first IVT injection of EYE201 once all 3 participants in the previous cohort have received their first dose of EYE201 and completed a predefined safety assessment, and a Dose Escalation Committee has confirmed the absence of dose-limiting toxicity (DLT).

Once the last participant in the MAD portion of the study has received their first dose, completed a predefined safety assessment, and the maximum tolerated dose (MTD) either has been determined or declared as not having been reached at the doses tested, 2 of the dose levels will be selected for inclusion in the Part 2 dose-finding study, based on safety and any preliminary efficacy signals observed.

The dose-finding part of the study will be randomized and masked to the participants and study site personnel (except the dose preparer and unmasked injecting physician). The study will be split according to whether the participants have treatment naïve or treatment experienced DME or NVAMD.

03

Conditions studied

  • Diabetic Macular Edema (DME)
  • Neovascular Age-related Macular Degeneration (NVAMD)
  • BRVO - Branch Retinal Vein Occlusion

Keywords

  • DME
  • Diabetic Macular Edema
  • NVAMD
  • Neovascular Age-related Macular Degeneration
  • BRVO
  • Branch Retinal Vein Occlusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

General Key Inclusion Criteria

  • Written before the first study-related activity
  • Be male or female ≥ 18 years of age
  • If female, have a negative serum pregnancy test at Screening and further negative urine tests immediately before each dose of study medication if the participant is a female of .

General Key Exclusion Criteria

  • Be pregnant or breastfeeding
  • Have a history of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of Screening
  • Have uncontrolled blood pressure, defined as systolic ≥180 mmHg and/or diastolic ≥100 mmHg while a participant is at rest.
  • Have had Yttrium-Aluminum Garnet laser capsulotomy in the study eye within 90 days of Screening
  • Have had Pan-retinal Photocoagulation or focal thermal laser photocoagulation in the study eye
  • Have tractional retinal detachment in the study eye
  • Have uncontrolled glaucoma (defined as IOP ≥ 25 mmHg despite treatment with antiglaucoma medication) in the study eye

BRVO-specific Inclusion Criteria

Participants must:

  • Be diagnosed with BRVO in the study eye
  • Have a ETDRS BCVA letter score between ≤ 70 and ≥ 35 (20/40 to 20/200 Snellen equivalent) in the study eye
  • Have a CST of ≥ 325 μm in the study eye on SDOCT as determined by the IRC at Screening
  • Have a decrease in vision in the study eye determined by the Investigator to be primarily the result of BRVO BRVO-specific Exclusion Criteria

Participants must not:

  • Have macular edema in the study eye considered to be secondary to a cause other than BRVO (e.g., DME, Irvine-Gass syndrome)
  • Have active iris or angle neovascularization or neovascular glaucoma in the study eye
  • Have proliferative retinopathy, central retinal vein occlusion, or hemiretinal vein occlusion

DME-specific Inclusion Criteria

Participants must:

  • Have Type 1 or Type 2 diabetes mellitus and a A1c (HbA1c) of ≤ 12%
  • Have a ETDRS BCVA letter score between ≤ 70 and ≥ 35 (20/40 to 20/200 Snellen equivalent) in the study eye
  • Have a CST of ≥ 325 μm in the study eye on SDOCT as determined by the IRC at Screening
  • Have a decrease in vision in the study eye determined by the Investigator to be primarily the result of DME

DME-specific Exclusion Criteria

Participants must not:

  • Have macular edema in the study eye considered to be secondary to a cause other than DME (eg, retinal vein occlusion, Irvine-Gass syndrome)
  • Have active iris or angle neovascularization or neovascular glaucoma in the study eye
  • Have high-risk proliferative diabetic retinopathy characteristics in the study eye

NVAMD-specific Inclusion Criteria

Participants must:

  • Be ≥ 50 years of age
  • Have a ETDRS BVCA letter score between ≤ 70 and ≥ 35 (20/40 to 20/200 Snellen equivalent) in the study eye
  • Subfoveal CNV secondary to AMD, with a total lesion size (including blood, scar/atrophy \& neovascularization) of ≤ 9-disc areas, of which at least 50% must be active CNV in the study eye
  • Have a CST of ≥ 325 μm in the study eye on SDOCT as determined by the IRC at Screening
  • Be treatment naïve with vision loss in the study eye secondary to NVAMD diagnosed within 21 days prior to the Day 1 study treatment NVAMD-specific Exclusion Criteria

Participants must not:

  • Have had previous thermal subfoveal laser therapy in the study eye
  • Have any subfoveal atrophy or scarring, blood over the fovea, or subfoveal fibrosis in the study eye. Additionally, no more than 25% of the total lesion size may be made up of scarring or atrophy
  • Have had previous photodynamic therapy with Visudyne in the study eye
  • Have diabetic retinopathy in the study eye
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Part 1 MAD - Low Dose

    Drug: EYE201

  • Experimental
    Part 1 MAD - Low-Mid Dose

    Drug: EYE201

  • Experimental
    Part 1 MAD - Mid-High Dose

    Drug: EYE201

  • Experimental
    Part 1 MAD - High Dose

    Drug: EYE201

  • Experimental
    Part 2: DME naïve or experienced participants - Dose 1

    Drug: EYE201

  • Experimental
    Part 2: DME naïve or experienced participants -Dose 2

    Drug: EYE201

  • Experimental
    Part 2: NVAMD naïve or experienced participants - Dose 1

    Drug: EYE201

  • Experimental
    Part 2: NVAMD naïve or experienced participants - Dose 2

    Drug: EYE201

Interventions

  • DrugEYE201

    EYE201 solution for intravitreal administration

    Also known as: Tiespectus, MK-8748

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Time frame: 12 Weeks

Secondary outcomes

  1. Best- Corrected Visual Acuity

    Time frame: 12 Weeks

07

Study locations

27 sites
  • Scottsdale, Arizona
    Scottsdale, Arizona 85255, United States
  • Modesto, CA
    Modesto, California 95356, United States
  • Mountain View, California
    Mountain View, California 94040, United States
  • Sacramento, CA
    Sacramento, California 95825, United States
  • Sacramento, California
    Sacramento, California 95841, United States
  • Deerfield Beach, FL
    Deerfield Beach, Florida 33064, United States
  • Lemont, IL
    Lemont, Illinois 60439, United States
  • Hagerstown, Maryland
    Hagerstown, Maryland 21740, United States
  • Madison, Mississippi
    Madison, Mississippi 39110, United States
  • Bloomfield, New Jersey
    Bloomfield, New Jersey 07003, United States
  • Asheville, NC
    Asheville, North Carolina 28803, United States
  • Wake Forest, NC
    Wake Forest, North Carolina 27587, United States
  • West Columbia, South Carolina
    West Columbia, South Carolina 29169, United States
  • Germantown, Tennessee
    Germantown, Tennessee 38138, United States
  • Knoxville, TN
    Knoxville, Tennessee 37922, United States
  • Nashville, Tennessee
    Nashville, Tennessee 37203, United States
  • Abilene, Texas
    Abilene, Texas 79606, United States
  • Amarillo, Texas
    Amarillo, Texas 79106, United States
  • Austin, Texas
    Austin, Texas 78705, United States
  • Bellaire, Texas
    Bellaire, Texas 77401, United States
  • Bellaire, TX
    Bellaire, Texas 77401, United States
  • Dallas, Texas
    Dallas, Texas 75231, United States
  • Plano, TX
    Plano, Texas 75075, United States
  • Round Rock, TX
    Round Rock, Texas 78681, United States
  • San Antonio, Texas
    San Antonio, Texas 78240, United States
  • Woodlands, Texas
    The Woodlands, Texas 77384, United States
  • Arecibo, PR
    Arecibo, 00612, Puerto Rico
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Mar 2026, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2024
First posted
Oct 29, 2024
StartActual
Nov 12, 2024
Primary completionActual
Mar 25, 2026
CompletionActual
Aug 11, 2026
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06664502
Lead sponsor
EyeBiotech Ltd.
Responsible party
Sponsor
First posted
Oct 29, 2024
Start date
Nov 12, 2024
Primary completion
Mar 25, 2026
Completion
Aug 11, 2026
Last update
Aug 24, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EYE201

Start the discussion